Docetaxel Versus Paclitaxel for Adjuvant Treatment of Ovarian Cancer: Case-Control Analysis of Toxicity

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 27, Issue 1, 2004, Pages 14-18

  Hsu, Yvonne ^a   Sood, Anil K ^a,b   Sorosky, Joel I ^a  

^a UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Docetaxel; Ovarian cancer; Paclitaxel; Toxicity

Indexed keywords

CARBOPLATIN; DEXAMETHASONE; DOCETAXEL; PACLITAXEL;

ADULT; AGE; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PATIENT; CANCER STAGING; CASE CONTROL STUDY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG HYPERSENSITIVITY; FEMALE; FEVER; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN TISSUE; LYMPHEDEMA; NAUSEA; NEPHROTOXICITY; NEUROPATHY; NEUTROPENIA; OVARY CANCER; PERITONEUM TUMOR; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT OUTCOME; UNIVERSITY HOSPITAL; UTERINE TUBE CARCINOMA;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CASE-CONTROL STUDIES; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; MIDDLE AGED; NEUTROPENIA; OVARIAN NEOPLASMS; PACLITAXEL; PERIPHERAL NERVOUS SYSTEM DISEASES; RETROSPECTIVE STUDIES; TAXOIDS; TREATMENT OUTCOME;

EID: 0842348926     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.coc.0000045849.95834.6B     Document Type: Article

References (30)

1. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and IV ovarian cancer. N Engl J Med 1996;334:1-6.
2. Ozols Rf, Bundy BN, Fowler JM, et al. Randomized Phase III Study of Cisplatin (CIS)/Paclitaxel (PAC) Versus Carboplatin (CARBO)/PAC in Optimal Stage III Epithelial Ovarian Cancer (OC): A Gynecologic Oncology Group Trial (GOG 158). Proc Am Soc Clin Oncol 1999;18:356a.
3. Bissery MC, Vrignaud P, Lavelle F. Preclinical profile of docetaxel (taxotere); efficacy as a single agent and in combination. Semin Oncol 1995;22:3-16.
4. Ringel L, Horwitz SB. Studies with RP 56976 (Taxotere): a semisynthetic analog of Taxol. J Natl Cancer Inst 1991;83:288-91.
5. Barasoain L, De Ines C, Diaz F, et al. Interaction of tubulin and cellular microtubules with Taxotere (RP56976), a new semisynthetic analog of Taxol. Proc Am Assoc Cancer Res 1991;32:329.
6. Gueritte-Voegelein F, Guenard D, Lavelle F, et al. Relationships between the structure of Taxol analogues and their antimitotic activity. J Med Chem 1991;34:992-8.
7. Verschraegen CF, Sittisomwong T, Kudelka AP, et al. Docetaxel for patients with paclitaxel-resistant m)llerian carcinoma. J Clin Oncol 2000;18:2733-9.
8. Kaye SB, Piccart M, Aapro M, et al. Phase II trials of docetaxel (Taxotere) in advanced ovarian cancer - an updated overview. Eur J Cancer 1997;33:2167-70.
9. Piccart MJ, Gore M, Ten Bokkel Huinink W, et al. Docetaxel: an active drug for treatment of advanced epithelial ovarian cancer. J Natl Cancer Inst 1995;87:676-81.
10. Francis P, Schneider J, Hann L, et al. Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer. J Clin Oncol 1994;12:2301-8.
11. Vasey PA, Paul J, Birt A, et al. Docetaxel and cisplatin in combination as first-line chemotherapy for advanced epithelial ovarian cancer. Scottish Gynaecological Cancer Trials Group. J Clin Oncol 1999;17:2069-80.
12. Vasey P, on behalf of the Scottish Gynaecologic Cancer Trials Group. Preliminary results of the SCOTROC Trial: a phase III comparison of paclitaxel-carboplatin (PC) and docetaxel-carboplatin (DC) as first-line chemotherapy for stage IC-IV epithelial ovarian cancer (EOC). Proc Am Soc Clin Oncol 2001;202a.
13. Menzin AW. GOG common toxicity criteria, appendix 3. In Rubin SC, ed. Chemotherapy of gynecologic cancers. Philadelphia: Lippincott-Raven, 1996:189-96.
14. Ozer H, Armitage JO, Bennett CL, et al. 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. J Clin Oncol 2000;18:3558-85.
15. Olson JK, Sood AK, Sorosky JI, et al. Taxol hypersensitivity: rapid retreatment is safe and cost effective. Gynecol Oncol 1998;68:25-8.
16. Calvert AH, Harland SJ, Newell DR, et al. Early clinical studies with cis-diammine-1, 1-cyclobutanedicarboxylate platinum II. Cancer Chemother Pharmacol 1982;9:140-7.
17. Taylor AE, Wiltshaw E, Gore ME, et al. Long-term follow-up of the first randomized study of cisplatin versus carboplatin for advanced epithelial ovarian cancer. J Clin Oncol 1994;12:2066-70.
18. Alberts DS, Green S, Hannigan EV, et al. Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology group of a phase III randomized trial in stages III and IV ovarian cancer. J Clin Oncol 1992;10:706-17.
19. Swenerton K, Jeffrey J, Stuart G, et al. Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: a randomized phase III study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1992;10:718-26.
20. Kavanagh JJ, Kudelka AP, de Leon CG, et al. Phase II study of docetaxel in patients with epithelial ovarian carcinoma refractory to platinum. Clin Cancer Res 1996;2:837-42.
21. Markman M, Kennedy A, Webster K, et al. Combination chemotherapy with carboplatin and docetaxel in the treatment of cancers of the ovary and fallopian tube and primary carcinoma of the peritoneum. J Clin Oncol 2001;19:1901-5.
22. Markman M, Kennedy A, Webster K, et al. Paclitaxel-associated hypersensitivity reactions: experience of the Gynecologic Oncology Program of the Cleveland Clinic Cancer Center. J Clin Oncol 2000;18:102-5.
23. Moon C, Verscharaegen CF, Bevers M, et al. Use of docetaxel (Taxotere) in patients with paclitaxel (Taxol) hypersensitivity. Anti Cancer Drugs 2000;11:565-8.
24. Bernstein BJ. Docetaxel as an alternative to paclitaxel after acute hypersensitivity reactions. Ann Pharm 2000;34:1332-5.
25. Markman M, Kennedy A, Webster K, et al. Neurotoxicity associated with a regimen of carboplatin (AUC 5-6) and paclitaxel (175 mg/m2 over 3h) employed in the treatment of gynecologic malignancies. J Cancer Res Clin Oncol 2001;127:55-8.
26. Hilkens PH, Pronk LC, Verweij J, et al. Peripheral neuropathy induced by combination chemotherapy of docetaxel and cisplatin. Br J Cancer 1997;75:417-22.
27. Kaye SB, Scottish Gynaecological Cancer Trials Group. The integration of docetaxel into first-line chemotherapy for ovarian cancer. Int J Gyn Cancer 2001;11(suppl 1):31-3.
28. Bando H, Miyata J, Sano T, et al. Retrospective analysis of administration of a combination of docetaxel and carboplatin for advanced non-small cell lung cancer. Anticancer Res 2001;21:2107-13.
29. Vasey PA, Atkinson R, Coleman R, et al. Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancer. Br J Cancer 2001;84:170-8.
30. Rubio-Terres C, Tisaire JL, Kobina S, et al. Cost-minimisation analysis of three regimens of chemotherapy (docetaxel-cisplatin, paclitaxel-cisplatin, paclitaxel-carboplatin) for advanced non-small-cell lung cancer. Lung Ca 2002;35:81-9.